The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke
Open accessAbstract
We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0–3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stroke-induced neurogenesis in aged brain
Darsalia, V., Heldmann, U., Lindvall, O., & Kokaia, Z. (2005) · Stroke · doi:10.1161/01.str.0000173151.36031.be · Cited by 240
One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke
Shen, L. H., Li, Y., Chen, J., Cui, Y., Zhang, C., Kapke, A., Lu, M., Savant-Bhonsale, S., & Chopp, M. (2007) · Stroke · doi:10.1161/strokeaha.106.481218 · Cited by 208
Liu, Z., Li, Y., Zhang, X., Savant-Bhonsale, S., & Chopp, M. (2008) · Stroke · doi:10.1161/strokeaha.107.511659 · Cited by 115
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Madrigal, M., Rao, K. S., & Riordan, N. H. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0260-8 · Cited by 615
Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., et al. (2012) · JAMA · doi:10.1001/jama.2012.316 · Cited by 553
Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments
George, P. M., & Steinberg, G. K. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.041 · Cited by 393
Hess, D. C., Wechsler, L. R., Clark, W. M., Savitz, S. I., Ford, G. A., Chiu, D., Yavagal, D. R., Uchino, K., Liebeskind, D. S., Auchus, A. P., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30046-7 · Cited by 367
Bronckaers, A., Hilkens, P., Martens, W., Gervois, P., Ratajczak, J., Struys, T., & Lambrichts, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.013 · Cited by 354
Hsieh, J.-Y., Wang, H.-W., Chang, S.-J., Liao, K.-H., Lee, I.-H., Lin, W.-S., Wu, C.-H., Lin, W.-Y., & Cheng, S.-M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072604 · Cited by 318
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases
Uccelli, A., Laroni, A., & Freedman, M. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70121-1 · Cited by 306
Dabrowska, S., Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1571-8 · Cited by 298
Thompson, M., Mei, S. H. J., Wolfe, D., Champagne, J., Fergusson, D., Stewart, D. J., Sullivan, K. J., Doxtator, E., Lalu, M., English, S. W., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.100249 · Cited by 283
Concise Review: Mesenchymal Stem Cell Treatment of the Complications of Diabetes Mellitus
Volarevic, V., Arsenijevic, N., Lukic, M. L., & Stojkovic, M. (2011) · Stem Cells · doi:10.1002/stem.556 · Cited by 265
The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
Cunningham, C. J., Redondo-Castro, E., & Allan, S. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18776802 · Cited by 242
Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases
Volkman, R., & Offen, D. (2017) · Stem Cells · doi:10.1002/stem.2651 · Cited by 222
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Staff, N. P., Jones, D. T., & Singer, W. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.001 · Cited by 150
New Evidence for Therapies in Stroke Rehabilitation
Dobkin, B. H., & Dorsch, A. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0331-y · Cited by 146
Nooshabadi, V. T., Mardpour, S., Yousefi‐Ahmadipour, A., Allahverdi, A., Izadpanah, M., Daneshimehr, F., Ai, J., Banafshe, H. R., & Ebrahimi‐Barough, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26726 · Cited by 133
Huat, T. J., Khan, A. A., Pati, S., Mustafa, Z., Abdullah, J. M., & Jaafar, H. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-91 · Cited by 129
“Autologous transplantation of MSCs in stroke patients was proven therapeutically effective [13].”
BackgroundLi, J., Zhang, Q., Wang, W., Lin, F., Wang, S., & Zhao, J. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10138-5 · Cited by 128
Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke
Wang, F., Tang, H., Zhu, J., & Zhang, J. H. (2018) · Cell Transplantation · doi:10.1177/0963689718795424 · Cited by 102
Effects of Severe Hypoxia on Bone Marrow Mesenchymal Stem Cells Differentiation Potential
Cicione, C., Muiños-López, E., Hermida-Gómez, T., Fuentes-Boquete, I., Díaz-Prado, S., & Blanco, F. J. (2013) · Stem Cells International · doi:10.1155/2013/232896 · Cited by 84
Tsang, K. S., Ng, C. P. S., Zhu, X. L., Wong, G. K. C., Lu, G., Ahuja, A. T., Wong, K. S. L., Ng, H. K., & Poon, W. S. (2017) · World Journal of Stem Cells · doi:10.4252/wjsc.v9.i8.133 · Cited by 49
Noh, J.-E., Oh, S.-H., Park, I.-H., & Song, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.546659 · Cited by 28
Engineering islets from stem cells: The optimal solution for the treatment of diabetes
Du, S., Li, Y., Geng, Z., Zhang, Q., Buhler, L. H., Gonelle-Gispert, C., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869514 · Cited by 9
The role of mesenchymal stem cells in oncology and regenerative medicine
Maliha, K., Syeda Ezze Rukhshan, A., & Amanda L, O. (2017) · Future Oncology · doi:10.2217/fon-2016-0264 · Cited by 5
Metadata
- Authors
- Lee, J. S., Hong, J. M., Moon, G. J., Lee, P. H., Ahn, Y. H., & Bang, O. Y.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-19
- Volume
- 28
- Issue
- 6
- Pages
- 1099-1106
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2029584195
- Cited by
- 779
- References
- 3
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.